As of 2025-12-19, the Relative Valuation of Intellia Therapeutics Inc (NTLA) is (59.08) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.88 USD, the upside of Intellia Therapeutics Inc based on Relative Valuation is -765.3%.
The range of the Relative Valuation is (53.50) - (66.20) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.9x - 17.2x | 15.0x |
| Forward P/E multiples | 13.9x - 17.4x | 15.6x |
| Fair Price | (53.50) - (66.20) | (59.08) |
| Upside | -702.5% - -845.5% | -765.3% |
| Date | P/E |
| 2025-12-18 | -2.31 |
| 2025-12-17 | -2.28 |
| 2025-12-16 | -2.37 |
| 2025-12-15 | -2.37 |
| 2025-12-12 | -2.34 |
| 2025-12-11 | -2.48 |
| 2025-12-10 | -2.43 |
| 2025-12-09 | -2.42 |
| 2025-12-08 | -2.45 |
| 2025-12-05 | -2.50 |
| 2025-12-04 | -2.53 |
| 2025-12-03 | -2.35 |
| 2025-12-02 | -2.10 |
| 2025-12-01 | -2.19 |
| 2025-11-28 | -2.34 |
| 2025-11-26 | -2.21 |
| 2025-11-25 | -2.22 |
| 2025-11-24 | -2.17 |
| 2025-11-21 | -2.13 |
| 2025-11-20 | -2.09 |
| 2025-11-19 | -2.14 |
| 2025-11-18 | -2.20 |
| 2025-11-17 | -2.20 |
| 2025-11-14 | -2.26 |
| 2025-11-13 | -2.25 |
| 2025-11-12 | -2.47 |
| 2025-11-11 | -2.64 |
| 2025-11-10 | -2.53 |
| 2025-11-07 | -2.47 |
| 2025-11-06 | -3.20 |
| 2025-11-05 | -3.53 |
| 2025-11-04 | -3.17 |
| 2025-11-03 | -3.40 |
| 2025-10-31 | -3.28 |
| 2025-10-30 | -3.19 |
| 2025-10-29 | -3.41 |
| 2025-10-28 | -3.63 |
| 2025-10-27 | -3.84 |
| 2025-10-24 | -6.65 |
| 2025-10-23 | -6.73 |
| 2025-10-22 | -6.39 |
| 2025-10-21 | -7.01 |
| 2025-10-20 | -7.27 |
| 2025-10-17 | -6.43 |
| 2025-10-16 | -6.47 |
| 2025-10-15 | -6.74 |
| 2025-10-14 | -6.21 |
| 2025-10-13 | -6.17 |
| 2025-10-10 | -6.37 |
| 2025-10-09 | -6.62 |